Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Endo USA Inc., a Keenova Therapeutics Company
Age
18–75
Sex
ALL
Healthy volunteers
Accepted
You may be eligible if
The subject enrolled in this study must have been previously randomized and dosed in the double-blind treatment period of study EN3202-016 or EN3202-019 and completed the exit visits for these studies.
Males or females, age 18 and 75 years, inclusively.
The subject continues to have chronic moderate to severe back or cancer pain that requires opioid medication. Women must continue to be of non-childbearing potential.
You may not be if
The subject experienced any serious drug related adverse events in studies EN3202-016 or EN3202-019.
The subject withdrew from EN3202-016 or EN3202-019 for a reason other than lack of efficacy.
Subjects with known allergies to opiate-class narcotic agents (morphine, codeine, hydrocodone, propoxyphene, meperidine, oxycodone, etc.) or naproxen, or subjects who have any medical condition in which opiates are medically contraindicated.
Clareo Health | Open-Label Extension to Evaluate the Long-Term Safety, Tolerability and Analgesic Efficacy
